Trial Profile

A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Derazantinib (Primary)
Indications Cholangiocarcinoma; Liver cancer
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms FIDES-01
Sponsors ArQule; Basilea Pharmaceutica

Most Recent Events

22 Nov 2022 Status changed from active, no longer recruiting to completed.
22 Nov 2022 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results assessing Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 fusions, mutations or amplifications presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com